Endoscopic sclerotherapy apparently improves the control of haemorrhage from oesophageal varices and prolongs survival.1 2 Several acute complications have been encountered: oesophagitis, necroses, ulcerations, tears, perforation, fistula formation, and mediastinitis, some of which, although rarely, have been fatal. 1-8 The inflammation and necroses followed by fibrosis might result in motility disturbances,&1°stncture and dysphagia. In clinical studies, however, these complications have been reported only occasionally. We investigated the occurrence of oesophageal stricture and dysphagia, their antecedents and the relation to the intensity and the effects of the treatment.
Methods

PATI ENTS
Fifty seven patients were admitted with haemorrhage from oesophageal varices and endoscopic sclerotherapy was started in all cases irrespective of the clinical assessment of liver function. The age range was 15-82 years with a median of 52 years. During the first three months after diagnosis of varices, 23 patients (40.4%) died, which mortality compares well with the natural history of this disease. "l As the oesophageal stricture and dysphagia are of clinical interest only for patients escaping the initial hazards of the disease, we selected for this report the 34 patients who survived three months or more. They were observed a median of 28 (range 3-47) months. Twenty five had alcoholic cirrhosis, six had nonalcoholic cirrhosis, and three had portal vein thrombosis. When the sclerotherapy began 14 had ascites and seven were in hepatic precoma, none in coma. 
SCLEROTHERAPY
Results
During the entire course of observation 20 of the 34 patients developed stricture and/or dysphagia; 14 stricture and dysphagia, two dysphagia without stricture, and four stricture without dysphagia. In the 20 patients, stricture and/or dysphagia were present during median 38% (range 1-86%) of their observation time (Fig. 1) . Both phenomena occurred intermittently and often independently of each other (Fig. 1) .
The time of first diagnosis of the stricture ranged from nine to 1229 days with a median of 206 days after start of sclerotherapy. At the first appearance of the stricture, eight out of the 18 patients presented a stricture not passable for the endoscope. Except in four patients all strictures were located to the lower 5 cm of the oesophagus. Ten of the patients complained of dysphagia at the time of stricture diagnosis.
The occurrence of oesophageal complications within each of the four years of observation may be assessed as the number of patients affected in per cent of the mean number of patients under observation during each year (Table) . About half of the patients suffered from dysphagia and/or stricture each year. Dysphagia for solid food occurred in about one third, whereas dysphagia for liquid food was rare, not exceeding 10 per cent. A stricture passable for the endoscope was found in about 20% each year. The frequency of stricture not passable increased from 13% to 33% during the four years. The correlation between occurrence of dysphagia and stricture was only moderate (Table) .
Endoscopic oesophageal dilatation (the EderPuestow technique to olive size no 45) was performed in 11 patients, two of whom had dysphagia without stricture (Fig. 1) . One patient developed a narrow stricture 5 cm above the cardia 14 months after start of treatment. Dilatation led to a transdiaphragmatic fistula. Surgical correction with fundoplication was followed by narrowing of the stricture necessitating 10 dilatations during 18 months.
The patients developing a stricture had received median eight treatments with a total of median 123 ml sclerosant (Fig. 2) . The median of the control values were 7.4 treatments and 93-0 ml sclerosant, and the differences were significant (p<0-01) (Fig.  2) . Until stricture was diagnosed, the amount of sclerosant given at each session was median 14 3 ml (range 11-9-23-3 ml) which was significantly more than the control value having a median of 12 7 ml (range 10-9-15-1 ml) (p<0-01). Four patients complained of dysphagia before the stricture was diagnosed; this was higher, but not significantly different from the control value of 1 69. Mucosal necroses were seen in 15 patients before stricture developed; the control value was 10(6 and significantly lower (p<0(02). Five patients had oesophageal ulcers before the stricture, and the control value was 2-67, but this difference was not significant.
Discussion
In this study stricture and/or dysphagia occurred in about half of the patients during the four years observation period after start of sclerotherapy. This is a higher incidence than reported in other studies. In a recent prospective trial including 51 patients assigned to sclerotherapy nine patients (18%) developed stricture, five of whom complained of dysphagia.2 An even lower incidence has been reported in the other studies.3-7 Our study is not directly comparable with these studies, however, as none of them has taken into account the time of occurrence, and the duration of the complications in relation to the changing number of patients under observation. On the other hand, the treatment was carried out more aggressively here than in most other studies. We injected sclerosant every third day against -for example, three to four weeks interval in the prospective trial.2 Also the extension of the treatment up to about 1f) cm proximal to the gastro-oesophageal junction, to which the treatment usually is restricted, may have contributed to the high incidence of dysphagia and stricture. The choice of the aggressive treatment regimen was made with the idea of offering the possible benefits of this treatment to the patients who are subject to the high initial mortality after the first episode of haemorrhage from varices.
The oesophageal complications occurred intermittently and were present in median 38% of the total observation time, but with a large inter-and intrapatient variation. The severity of the complications is shown by the findings of some patients complaining of dysphagia for liquids, of a frequency of narrow strictures increasing from 13% through 33c%,, and the necessity of dilatation in 11 patients.
Dysphagia was not always ascribable to a detectable stricture and several patients had strictures not resulting in dysphagia. The inflammation and ulceration of the oesophageal mucosa may cause motility disturbances with dysphagia.9 "' On the other hand, presence of a stricture without dysphagia might reflect an uncertain interpretation of the endoscopic findings as well as a variable subjective threshold for dysphagia.
The sclerotherapy has many variables of possible influence on the development of dysphagia and stricture: intra-vs paravariceal injection, amount, concentration and type of sclerosant, the vehicle of the sclerosant, the number of injections per treatment, depth of and distance between injections, total number and time interval between the treatments. criteria for interruption and cessation of treatment. We examined the relation to the cumulated number of treatments and amounts of sclerosant. The stricture patients had most treatments with greatest amount of sclerosant, but this did not distinguish them clearly from those without stricture.
It is plausible that less aggressive treatment might prevent stricture formation, but this will probably be at the expense of an increased risk of recurrent variceal bleeding. In our study, the patients developing strictures showed tendencies to greater varices at start of treatment, slightly more effective eradication of varices and a shorter observation time without recurrent bleeding. Although these differ- 
